Rafael pharmaceuticals receives fda fast track designation for cpi-613® (devimistat) for the treatment of pancreatic cancer

Cranbury, n.j., nov. 10, 2020 (globe newswire) -- rafael pharmaceuticals, inc. (“rafael” or the “company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the u.s. food and drug administration (fda) has granted fast track designation for the company's lead compound, cpi-613® (devimistat), for the treatment of metastatic pancreatic cancer. 
RFL Ratings Summary
RFL Quant Ranking